Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 25.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Wave Life Sciences was 46.70% per year. The lowest was -149.30% per year. And the median was 7.60% per year.
Wave Life Sciences (NAS:WVE) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Wave Life Sciences 5-Year EBITDA Growth Rate Related Terms
WVE vs IMMX, CADL, ARDX: 5-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Wave Life Sciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wave Life Sciences 5-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wave Life Sciences's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Wave Life Sciences's 5-Year EBITDA Growth Rate falls into.
Wave Life Sciences 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 25.00% mean?
Wave Life Sciences (WVE) has a 5-Year EBITDA Growth Rate of 25.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Wave Life Sciences and its competitors.
Is Wave Life Sciences' 5-Year EBITDA Growth Rate too high?
Wave Life Sciences' current 5-Year EBITDA Growth Rate is 25.00%. Overall, Wave Life Sciences has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' 5-Year EBITDA Growth Rate compare to IMMX and CADL?
Wave Life Sciences' 5-Year EBITDA Growth Rate of 25.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Wave Life Sciences and its competitors. Wave Life Sciences's current 5-Year EBITDA Growth Rate is 25.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.89, compared to a current price of $4.85 — trading 24.7% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 25.00%. Wave Life Sciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current 5-Year EBITDA Growth Rate is 25.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wave Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued.
The current stock price of $4.85 is trading 24.7% above its estimated GF Value™ of $3.89.
GuruFocus considers Wave Life Sciences to be Modestly Overvalued.
Key valuation signals for WVE:
5-Year EBITDA Growth Rate: 25.00%
GF Value™: $3.89 vs. price of $4.85 (24.7% above fair value)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
60GF Score
Get the complete analysis for WVE
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
